In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Clinical Trials - Hot Lines

ESC Congress 2018

These sessions are reserved for first presentation of the primary endpoint(s) of novel clinical trials, recently completed and unpublished. Each will immediately be followed by a review from a renowned expert on the outcome presented.

New this year –The audience will be invited to interact during the presentations by answering questions when prompted and by using "Ask" to send their questions directly to the Mobile App. Incoming questions Moderator.

Use your Mobile App to answer and send questions during the session.


Hot Line Session 1

Sunday 26 August - 14:30 - 15:45     Munich - Main Auditorium

MARINER - Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk

CAMELLIA-TIMI 61 - Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61

ARRIVE - Aspirin to Reduce Risk of Initial Vascular Events


Hot Line Session 2

Sunday 26 August - 16:45 - 17:45     Munich – Main Auditorium

ASCEND - A randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes

ASCEND - A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 people with diabetes

ART - Randomised comparison of bilateral versus single internal thoracic coronary artery bypass graft surgery: effects on mortality at ten years follow-up in the Arterial Revascularisation Trial    


Hot Line Session 3

Monday 27 August - 11:00 - 12:30     Munich – Main Auditorium

ATTR-ACT - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure study - A randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation and reduced left ventricular ejection fraction

GLOBAL LEADERS TRIAL  - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapy

Hot Line Session 4

Tuesday 28 August - 11:00 - 12:30     Munich – Main Auditorium

PURE - Association of dietary quality and risk of cardiovascular disease and mortality in more than 218,000 people from over 50 countries

FREED - Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy

BASKET-SMALL 2 - Drug-Coated Balloons vs. Drug- Eluting Stents in Small Vessel Interventions

VERDICT - Early versus deferred invasive examination and treatment of patients with Non-ST-segment elevation acute coronary syndrome


Hot Line Session 5

Tuesday 28 August - 14:30 - 15:45     Munich – Main Auditorium

High-STEACS - High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome

POET - Partial oral treatment of left-sided infectious endocarditis

AIMS - Aortic Irbesartan Marfan Study


Also not to be missed – Meet the Trialist sessionsView details

These sessions provide an unique opportunity for a focus on the trial with direct interaction with the audience. An opportunity for a deep-dive in the trial with the presenter and an expert in the topic animating discussions with questions to both the presenter and the audience.